Creatine Treatment in Psychiatric Disorders
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Creatine plays a pivotal role in brain energy homeostasis. Creatine supplementation is widely used in enhancing sports performance, and has been tried in the treatment of neurological, neuromuscular and atherosclerotic disease with a paucity of side effects.
Dechent et al (1999) studied the effect of oral creatine supplementation for 4 wk demonstrating a statistically significant increase of mean concentration of total creatine across brain regions. These findings suggest the possibility of using oral creatine supplementation to modify brain high-energy phosphate metabolism in subjects with various brain disorders, including schizophrenia and major depression. Recently, Rae et al (2003) reported that creatine supplementation for 6 weeks had a significant positive effect on both working memory and Raven matrices. Several independent lines of evidence suggest the possible involvement of altered cerebral energy metabolism in schizophrenia.
We are performing a double blind cross-over study of creatine in schizophrenia.
Forty patients will be treated with creatine for 3 months in a double-blind crossover design. Rating scales will include scales for assessing negative and positive symptoms of schizophrenia, clinical global impressions scale, scales for side-effects and a cognitive battery
Creatine effects on brain energy metabolism and its possible cognitive enhancing properties raise the possibility of developing a new therapeutic strategy in schizophrenia focusing on treating metabolic hypoactive brain areas including frontal regions.
| Condition | Intervention | Phase |
|---|---|---|
|
Schizophrenia |
Drug: creatine |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial |
- Positive and Negative Syndrome Scale [ Designated as safety issue: No ]
- Clincal Global Impression
| Enrollment: | 12 |
| Study Start Date: | September 2004 |
| Study Completion Date: | March 2006 |
| Primary Completion Date: | March 2006 (Final data collection date for primary outcome measure) |
Show Detailed Description Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- age 18-60
- physically healthy
- at least 2 years of illness in a stable condition
- presenting negative and cognitive symptoms
Exclusion Criteria:
- drug or alcohol abuse
- clinically significant medical condition
- laboratory abnormality
Contacts and Locations| Israel | |
| Beersheva Mental Health Center | |
| Beersheva, Israel | |
| Study Director: | RH Belmaker, MD | Ben Gurion University of the Negev + Beersheva Mental Health Center |
More Information
No publications provided by Beersheva Mental Health Center
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00140192 History of Changes |
| Other Study ID Numbers: | BMHC-3835 |
| Study First Received: | August 31, 2005 |
| Last Updated: | July 28, 2009 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Beersheva Mental Health Center:
|
creatine metabolism schizophrenia energy metabolism |
Additional relevant MeSH terms:
|
Mental Disorders Schizophrenia Schizophrenia and Disorders with Psychotic Features |
ClinicalTrials.gov processed this record on May 22, 2013